Back to top
more

Exact Sciences (EXAS)

(Delayed Data from NSDQ)

$56.72 USD

56.72
1,625,021

+0.53 (0.94%)

Updated Oct 3, 2025 04:00 PM ET

After-Market: $56.60 -0.12 (-0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

by Zacks Equity Research

Investors remain optimistic about Exact Sciences (EXAS) due to its strategic prioritization and positive solvency.

Zacks Equity Research

Exact Sciences (EXAS) Aided by Innovation, Strategic Buyouts

by Zacks Equity Research

Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need.

Zacks Equity Research

Are Medical Stocks Lagging Exact Sciences (EXAS) This Year?

by Zacks Equity Research

Here is how Exact Sciences (EXAS) and Anebulo Pharmaceuticals, Inc. (ANEB) have performed compared to their sector so far this year.

Zacks Equity Research

The Zacks Analyst Blog Highlights Adobe, S&P Global, Arista Networks, Cincinnati Financial and Exact Sciences

by Zacks Equity Research

Adobe, S&P Global, Arista Networks, Cincinnati Financial and Exact Sciences are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Adobe, S&P Global & Arista Networks

by Sheraz Mian

Today's Research Daily features new research reports on 12 major stocks, including Adobe Inc. (ADBE), S&P Global Inc. (SPGI) and Arista Networks, Inc. (ANET).

Zacks Equity Research

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Zacks Equity Research

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Zacks Equity Research

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FXH

Zacks Equity Research

Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?

by Zacks Equity Research

Sector ETF report for FXH

Zacks Equity Research

Exact Sciences (EXAS) Gains From New Buyouts Amid Rising Costs

by Zacks Equity Research

Exact Sciences (EXAS) is improving customer experience by making it simpler to order Cologuard electronically and continue re-screening of patients every three years.

Zacks Equity Research

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS), backed by Cologuard growth and upbeat guidance.

Zacks Equity Research

Exact Sciences' (EXAS) OncoExtra Test Selected for ComboMATCH

by Zacks Equity Research

Exact Sciences' (EXAS) Laboratory and OncoExtra test gets selected by the NCI for ComboMATCH trials.

Zacks Equity Research

Should Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for PRFZ

Zacks Equity Research

Exact Sciences (EXAS) Beats on Q2 Earnings, Ups '23 Sales View

by Zacks Equity Research

Strength in Screening revenues and Precision Oncology drive Exact Sciences (EXAS) Q2 performance.

Zacks Equity Research

Here's What Key Metrics Tell Us About Exact Sciences (EXAS) Q2 Earnings

by Zacks Equity Research

Although the revenue and EPS for Exact Sciences (EXAS) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Exact Sciences (EXAS) delivered earnings and revenue surprises of 10% and 3.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Are Medical Stocks Lagging Abcam (ABCM) This Year?

by Zacks Equity Research

Here is how Abcam PLC Sponsored ADR (ABCM) and Exact Sciences (EXAS) have performed compared to their sector so far this year.

Zacks Equity Research

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks Equity Research

Is Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PRFZ

Zacks Equity Research

What's in Store for Abbott Laboratories (ABT) in Q2 Earnings?

by Zacks Equity Research

The recent FDA approvals and growing customer demand for core therapeutic lines is likely to have driven Abbott's (ABT) Q2 performance.

Zacks Equity Research

The Zacks Analyst Blog Highlights DraftKings, Celsius Holdings, Marriott International, Copart and Exact Sciences

by Zacks Equity Research

DraftKings, Celsius Holdings, Marriott International, Copart and Exact Sciences are part of the Zacks top Analyst Blog.